Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of MRX-I Versus Linezolid in Adult Subjects With Acute Bacterial Skin and Skin Structure Infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Contezolid (Primary) ; Linezolid
Indications Abscess; Bacterial skin diseases; Cellulitis; Erysipelas; Skin and soft tissue infections; Wound infections
Focus Adverse reactions; Therapeutic Use
Sponsors MicuRx Pharmaceuticals

Most Recent Events

07 Oct 2016 Status changed from active, no longer recruiting to completed, as reported by a MicuRx Pharmaceuticals.
03 Nov 2015 Top-line results published in a MicuRx media release.
31 Aug 2015 According to a MicuRx Pharmaceuticals media release, results from this trial are expected to be available in the fourth quarter of 2015.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com